FILTER

FILTERED INTERVIEW RESULTS

Jeff Butler

PRESIDENT, AMPAC FINE CHEMICALS
"AFC’s core technology differentiators include energetic chemistry, high potency manufacturing, and extensive chromatographic separation capabilities."

Tyrone Brewer

PRESIDENT, US ONCOLOGY, JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
"I am excited about Janssen’s aspirational vision to eliminate cancer. With targeted therapies and immunotherapies, cancer treatment can be more effective and less toxic, enabling individuals to manage their disease while also maintaining their quality of life."

Joe Panetta

PRESIDENT AND CEO, BIOCOM CALIFORNIA
"The lifecycle of new product introduction into the market will now be shorter, as companies have fewer years to recover revenue as a result of the IRA."

Andrea Confetti & Roberto Fanelli

EXCLUSIVE SYNTHESIS BUSINESS UNIT LEADER (AC) & CATALOGUE APIS BU DEPUTY MANAGER (RF), DIPHARMA FRANCIS
RF: "Our experience in developing proprietary chemical processes and alternative solutions to support the generic API industry has been instrumental in rapidly expanding our CDMO activities."

Daniel Palmacci

PRESIDENT, CELL & GENE DIVISION, LONZA
"We want to give patients the best access to the amazing technology and treatments being developed by cell and gene therapy innovators. This is the modality with the greatest potential in the healthcare industry today."

John Patrick Oroho

PRESIDENT AND GENERAL MANAGER, PORZIO LIFE SCIENCES
"We are always looking at new regulations in the US and worldwide: laws very seldom change incrementally, so we adapt our systems to reflect that."

Michael Quirmbach

CEO AND PRESIDENT, CORDENPHARMA
"Our main mission is the execution of a >€200 million investment into CapEx projects that will bring additional capacity and technologies online to support pharma and biotech customers as their drug development projects progress."

Christiana Bardon

CO-MANAGING PARTNER, MPM | BIOIMPACT CAPITAL
"We see this as an exciting time to be investing in record-high levels of innovation at very attractive valuations."

Debbie Hart

PRESIDENT AND CEO, BIONJ
"To ensure that New Jersey maintains this leadership position, BioNJ will continue to work with State government to support industry and stave off onerous proposals. "

Jay Shukla

PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS, INC.
"Our partners benefit from our market intelligence and cost-splitting, and we attain the manufacturing capability and resources. We will continue to grow our partnership model now that we are expecting to double our revenue."

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

Mexico Chemicals 2024

In August 2023, Mexican exports to the US surpassed China for the first time. As companies prioritize securing supply their chains after years of logistics challenges, Mexico has begun to see major benefits. With a spate of new infrastructure projects such as the Interoceanic Corridor of the Isthmus of Tehuantepec coming online in 2023, the country is actively opening itself to investment. The chemical industry, in particular, is positioned for nearshoring-driven growth.

PARTNER EVENTS